New Report Highlights Global Trends and Advances in Chronic Lymphocytic Leukemia Research and Treatment
11 July 2024 - 8:41PM
Novotech, the global full-service clinical Contract Research
Organization (CRO) that partners with biotech companies to
accelerate the development of advanced and novel therapeutics at
every phase, has today released a significant research report
entitled
Chronic Lymphocytic Leukemia (CLL) - Global
Clinical Trial Landscape.
This expert monthly report, provided by the Novotech research
analyst team, is free of charge. It highlights promising new
developments in CLL research and therapies, offering
industry-leading and in-depth analysis of the disease’s
epidemiology, clinical trial activity, treatment options, and
funding landscape. The analysis identifies the exciting progress
being made in CLL research, and key opportunities for advancing
treatment strategies globally.
CLL, a slow-growing leukemia affecting older adults, has shown
diverse epidemiological patterns across different regions. In 2022,
an estimated 121,000 CLL cases were documented globally, with
Europe and North America accounting for the majority. Europe
reported close to 32,000 cases, led by Germany with 4,500 cases.
The United States alone contributed approximately 19,000 cases.
The incidence of CLL in Asia is generally lower than in Western
countries, with China reporting 10 to 20 times fewer cases than the
United States. Asia has an estimated nearly 11,000 cases, with
China and India accounting for around 4,000 and 2,000 cases,
respectively. In other Asian locations, including Japan, the
Philippines, Thailand, South Korea, and Malaysia, the collective
estimated CLL incidence surpassed 1,500 cases.
Treatment for CLL varies based on genetic markers, disease
stage, and prior treatment responses. The National Comprehensive
Cancer Network (NCCN) and the European Society for Medical Oncology
(ESMO) provide guidelines that emphasize targeted therapies and
immunotherapies. The development of drugs like Bruton’s Tyrosine
Kinase inhibitors (BTKis) and BCL-2 inhibitors, as well as
advancements in CAR T-cell therapy, represent significant strides
in improving patient outcomes.
The clinical trial landscape for CLL shows a robust global
effort to advance treatment options and understand the disease.
Since 2019, over 1,000 clinical trials have been initiated
worldwide, with North America leading at 37% of these trials,
followed closely by the Asia-Pacific region at 34%, Europe at 20%,
and the rest of the world (ROW) at 8%. Within North America, the
United States hosts the vast majority, accounting for 85% of all
North American trials. In Asia-Pacific, Mainland China plays a
pivotal role, conducting 44% of trials in the region and in Europe
Novotech’s research found significant participation from countries
like Spain, France, and Italy.
Interestingly, despite the lower incidence of CLL in Asian
countries, the report uncovered that the Asia-Pacific region
exhibits a trial density about seven times lower than the United
States and approximately three times lower than Europe. This
discrepancy highlights both the potential for increased research
engagement in Asia-Pacific countries and the relative concentration
of clinical trial activity in more densely populated regions.
The report also provides a SWOT analysis, highlighting the
strengths in targeted therapies and advanced diagnostics.
Opportunities lie in next-generation therapies and personalized
treatment approaches, while challenges include high treatment costs
and potential drug resistance.
Key takeaways from the report:
- The average enrolment period in the United States is 43.92
months, significantly longer than Asia-Pacific’s 21.70 months, yet
both regions show similar recruitment efficiency.
- CLL drug development includes 24 drugs in preclinical stages,
33 in Phase I, 30 in Phase II, and 4 in Phase III. Additionally, 5
drugs have received approval, and 26 are already marketed.
- The majority of marketed drugs for CLL are DNA Synthesis
inhibitors and B Lymphocyte Antigen CD20 inhibitors. Bruton
Tyrosine Kinase inhibitors dominate ongoing Phase III trials.
- From 2019 to 2023, China led venture capital funding for CLL
research with $1,813 million, followed closely by the United States
with $1,805.6 million. The CLL Society and the CLL Foundation in
the United States play significant roles in funding CLL research
and supporting patients.
- Significant advancements outlined in the report in targeted
therapies, immunotherapy (CAR T-cell therapy), and precision
medicine have improved CLL treatment outcomes. Companies like
AbbVie Inc., BeiGene Ltd., and Celltrion Inc. are actively
developing new therapies, paving the way for improved management of
this complex disease.
- Future research is exploring mitochondrial, glucose, glutamine,
and lipid pathways as therapeutic targets, while high treatment
costs and potential drug resistance pose challenges.
Download the report here
About
Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical
Contract Research Organization (CRO) focused on partnering with
biotech companies to accelerate the development of advanced and
novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has
received numerous prestigious awards, including the CRO Leadership
Award 2023, the Asia Pacific Cell & Gene Therapy Clinical
Trials Excellence 2023, the Asia-Pacific Contract Research
Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including
laboratories, Phase I facilities, drug development consulting,
regulatory expertise, and has experience with over 5,000 clinical
projects, including Phase I to Phase IV clinical trials and
bioequivalence studies. With a presence in 34 office locations and
a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member
visit www.Novotech-CRO.com
Media Contact
David James
mediacontact@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427